The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease
- PMID: 32231672
- PMCID: PMC7082402
- DOI: 10.3389/fimmu.2020.00454
The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease
Abstract
Sickle cell disease (SCD) is a genetic disease caused by a single mutation in the β-globin gene, leading to the production of an abnormal hemoglobin called hemoglobin S (HbS), which polymerizes under deoxygenation, and induces the sickling of red blood cells (RBCs). Sickled RBCs are very fragile and rigid, and patients consequently become anemic and develop frequent and recurrent vaso-occlusive crises. However, it is now evident that SCD is not only a RBC rheological disease. Accumulating evidence shows that SCD is also characterized by the presence of chronic inflammation and oxidative stress, participating in the development of chronic vasculopathy and several chronic complications. The accumulation of hemoglobin and heme in the plasma, as a consequence of enhanced intravascular hemolysis, decreases nitric oxide bioavailability and enhances the production of reactive oxygen species (ROS). Heme and hemoglobin also represent erythrocytic danger-associated molecular pattern molecules (eDAMPs), which may activate endothelial inflammation through TLR-4 signaling and promote the development of complications, such as acute chest syndrome. It is also suspected that heme may activate the innate immune complement system and stimulate neutrophils to release neutrophil extracellular traps. A large amount of microparticles (MPs) from various cellular origins (platelets, RBCs, white blood cells, endothelial cells) is also released into the plasma of SCD patients and participate in the inflammation and oxidative stress in SCD. In turn, this pro-inflammatory and oxidative stress environment further alters the RBC properties. Increased pro-inflammatory cytokine concentrations promote the activation of RBC NADPH oxidase and, thus, raise the production of intra-erythrocyte ROS. Such enhanced oxidative stress causes deleterious damage to the RBC membrane and further alters the deformability of the cells, modifying their aggregation properties. These RBC rheological alterations have been shown to be associated to specific SCD complications, such as leg ulcers, priapism, and glomerulopathy. Moreover, RBCs positive for the Duffy antigen receptor for chemokines may be very sensitive to various inflammatory molecules that promote RBC dehydration and increase RBC adhesiveness to the vascular wall. In summary, SCD is characterized by a vicious circle between abnormal RBC rheology and inflammation, which modulates the clinical severity of patients.
Keywords: heme; inflammation; oxidative stress; red blood cell; sickle cell disease.
Copyright © 2020 Nader, Romana and Connes.
Figures
Similar articles
-
Vascular pathophysiology of sickle cell disease.Presse Med. 2023 Dec;52(4):104202. doi: 10.1016/j.lpm.2023.104202. Epub 2023 Nov 7. Presse Med. 2023. PMID: 37944640 Review.
-
Vasculopathy and pulmonary hypertension in sickle cell disease.Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15;308(4):L314-24. doi: 10.1152/ajplung.00252.2014. Epub 2014 Nov 14. Am J Physiol Lung Cell Mol Physiol. 2015. PMID: 25398989 Free PMC article. Review.
-
Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.Compr Physiol. 2021 Apr 1;11(2):1785-1803. doi: 10.1002/cphy.c200024. Compr Physiol. 2021. PMID: 33792905
-
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry.J Vis Exp. 2019 Nov 5;(153). doi: 10.3791/60213. J Vis Exp. 2019. PMID: 31762454
-
Blood rheology and vascular function in sickle cell trait and sickle cell disease: From pathophysiological mechanisms to clinical usefulness.Clin Hemorheol Microcirc. 2024;86(1-2):9-27. doi: 10.3233/CH-238122. Clin Hemorheol Microcirc. 2024. PMID: 38073384 Review.
Cited by
-
Mitochondrial retention in mature red blood cells from patients with sickle cell disease is associated with stress erythropoiesis but not with proinflammatory state.Hemasphere. 2024 Oct 28;8(11):e70030. doi: 10.1002/hem3.70030. eCollection 2024 Nov. Hemasphere. 2024. PMID: 39473454 Free PMC article. No abstract available.
-
Targeting Neutrophil Adhesive Events to Address Vaso-Occlusive Crisis in Sickle Cell Patients.Front Immunol. 2021 Apr 28;12:663886. doi: 10.3389/fimmu.2021.663886. eCollection 2021. Front Immunol. 2021. PMID: 33995392 Free PMC article. Review.
-
Assessing the Impact of COVID-19 Vaccines on Sickle Cell Anaemia Patients: A Comparative Analysis of Biochemical and Haematological Parameters.Biomedicines. 2023 Aug 5;11(8):2203. doi: 10.3390/biomedicines11082203. Biomedicines. 2023. PMID: 37626700 Free PMC article.
-
Flurbiprofen inhibits heme induced NLRP3 inflammasome in Berkeley sickle cell disease mice.Front Pharmacol. 2023 Apr 26;14:1123734. doi: 10.3389/fphar.2023.1123734. eCollection 2023. Front Pharmacol. 2023. PMID: 37180702 Free PMC article.
-
Erythrocyte microRNAs: a tiny magic bullet with great potential for sickle cell disease therapy.Ann Hematol. 2021 Mar;100(3):607-614. doi: 10.1007/s00277-020-04390-y. Epub 2021 Jan 4. Ann Hematol. 2021. PMID: 33398452 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
